Alliqua BioMedical, Inc. (NASDAQ:ALQA) Files An 8-K Entry into a Material Definitive Agreement

Alliqua BioMedical, Inc. (NASDAQ:ALQA) Files An 8-K Entry into a Material Definitive Agreement

Story continues below

Item 1.01

Entry into a Material Definitive Agreement.

As previously reported, on March 29, 2017, Alliqua BioMedical,
Inc. (the Company) entered into an underwriting agreement (the
Underwriting Agreement) with H.C. Wainwright Co., LLC (the
Underwriter), relating to an underwritten public offering of
9,473,250 shares of the Companys common stock, par value $0.001
per share (the Common Stock), to which the Company agreed to
issue to the Underwriter or its designees warrants to purchase up
to 236,831 shares of Common Stock.

On April 3, 2017, to the Underwriting Agreement, the Company
issued warrants to purchase an aggregate of 236,831 shares of
Common Stock to the Underwriter and its designees (collectively,
the Underwriter Warrants). The Underwriter Warrants are
immediately exercisable and expire on March 29, 2022. The
Underwriter Warrants have an exercise price of $0.44 per share of
Common Stock.

The foregoing description of the Underwriter Warrants does not
purport to be complete and is qualified in its entirety by
reference to the full text of the Form of Underwriter Warrant, a
copy of which is attached hereto as Exhibit 4.1 and incorporated
herein by reference.

Item 8.01 Other Events.

On April 3, 2017, the Company issued a press release announcing
the closing of the underwritten public offering of its Common
Stock. A copy of the press release is attached to this Current
Report on Form 8-K as Exhibit 99.1 and is incorporated herein by
reference.

Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit Number Description
4.1 Form of Underwriter Warrant, dated April 3, 2017.
99.1 Press release dated April 3, 2017.


About Alliqua BioMedical, Inc. (NASDAQ:ALQA)

Alliqua BioMedical, Inc. is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc. and Choice Therapeutics, Inc. The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds. The Company utilizes hydrogel technology through which hydrogels are manufactured by introducing a hydrophilic polymer into water to create a feed mix. The Company’s commercial wound care portfolio consists of over four product categories, such as Human Biologics; Antimicrobial Protection; Exudate Management and Contract Manufacturing. Human Biologics include BIOVANCE and Extracellular Matrix (ECM). Under Antimicrobial Protection, the Company offers TheraBond 3D Antimicrobial Barrier Systems and SilverSeal.

Alliqua BioMedical, Inc. (NASDAQ:ALQA) Recent Trading Information

Alliqua BioMedical, Inc. (NASDAQ:ALQA) closed its last trading session down -0.031 at 0.454 with 745,552 shares trading hands.

An ad to help with our costs